Risk factors for lung cancer with coronary artery diseases and the advances of treatment_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

YAN Linan ¹ , DU Lin ² , ZHANG Xun ² , WEI Dong ¹ , YANG Dongyan ¹ , LI Junshan ¹ ,  WANG Lianqun ¹

1. Department of Cardiovascular Surgery, Tianjin Chest Hospital, Tianjin, 300222, P. R. China;
2. Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin, 300222, P. R. China;

Corresponding author：

WANG Lianqun, Email: Wlqxkyy@163.com

Keywords：

Lung cancer; coronary artery disease; risk factor; surgical treatment; review

DOI：

10.7507/1007-4848.202303032

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The coronary artery disease is a frequent severe disease of cardiovascular system in recent years. Meanwhile, lung cancer, with its high morbidity and mortality, is the most frequent malignant tumor of respiratory system in the world. Clinical studies have shown that the incidence of coronary artery disease and lung cancer is high throughout the year, and comorbidities are becoming more common, especially in elderly patients. The incidence of lung cancer and coronary heart disease may be related. This article summarizes the common risk factors (smoking and environmental pollution, fibrinogen, estrogen, and age), and treatment (surgical treatment, neoadjuvant therapy, and targeted therapy) progress of the two diseases, providing a theoretical basis for clinical prevention and treatment.

Citation： YAN Linan, DU Lin, ZHANG Xun, WEI Dong, YANG Dongyan, LI Junshan, WANG Lianqun. Risk factors for lung cancer with coronary artery diseases and the advances of treatment. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2024, 31(8): 1229-1234. doi: 10.7507/1007-4848.202303032 Copy

1.
2.
3.
4.
5.
6.
7.
8.
9.	Seebacher V, Polterauer S, Grimm C, et al. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: A multi-centre trial. Br J Cancer, 2010, 102(6): 952-956.
10.
11.	Tani Y, Kaneda H, Koh Y, et al. The impact of estrogen receptor expression on mutational status in the evolution of non-small cell lung cancer. Clin Lung Cancer, 2023, 24(2): 165-174.
12.
13.
14.
15.
16.	Ciriaco P, Carretta A, Calori G, et al. Lung resection for cancer in patients with coronary arterial disease: Analysis of short-term results. Eur J Cardiothorac Surg, 2002, 22(1): 35-40.
17.
18.	Dardzińska JA, Małgorzewicz S, Szupryczyńska N, et al. Adherence to the 2021 dietary guidelines of the European Society of Cardiology on cardiovascular disease prevention in residents of the Pomeranian Voivodeship with increased cardiovascular risk. Pol Arch Intern Med, 2023, 133(6): 16418.
19.	Sun M, Yang Q, Li M, et al. Association between the severity of coronary artery disease and lung cancer: A pilot cross-sectional study. Arq Bras Cardiol, 2022, 118(2): 478-485.
20.	郭凡. 非小细胞肺癌合并冠心病行同期手术治疗的研究. 天津医科大学, 2020.Guo F. Combined surgery in patients with nonsmall cell lung cancer accompanied bycoronary artery disease. Tianjin Medical University, 2020.
21.
22.	Tourmousoglou CE, Apostolakis E, Dougenis D. Simultaneous occurrence of coronary artery disease and lung cancer: What is the best surgical treatment strategy? Interact Cardiovasc Thorac Surg, 2014, 19(4): 673-681.
23.
24.
25.
26.
27.
28.
29.	Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage ⅢB/Ⅳ non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase Ⅱ study. J Clin Oncol, 2012, 30(17): 2046-2054.
30.	Meng Y, Li L, Wang H, et al. Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: A case report. Ann Transl Med, 2022, 10(8): 496.
31.	Hu X, Shui Y, Hirano H, et al. PD-L1 antibody enhanced β-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model. Cancer Immunol Immunother, 2023, 72(3): 719-731.
32.	Alduais Y, Zhang H, Fan F, et al. Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. Medicine (Baltimore), 2023, 102(8): e32899.
33.	Ganti AKP, Loo BW, Bassetti M, et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2021, 19(12): 1441-1464.
34.	Markovic M, Mitrovic S, Dagovic A, et al. Does the expression of vascular endothelial growth factor (VEGF) and Bcl-2 have a prognostic significance in advanced non-small cell lung cancer? Healthcare (Basel), 2023, 11(3): 292.

1.
2.
3.
4.
5.
6.
7.
8.
9. Seebacher V, Polterauer S, Grimm C, et al. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: A multi-centre trial. Br J Cancer, 2010, 102(6): 952-956.
10.
11. Tani Y, Kaneda H, Koh Y, et al. The impact of estrogen receptor expression on mutational status in the evolution of non-small cell lung cancer. Clin Lung Cancer, 2023, 24(2): 165-174.
12.
13.
14.
15.
16. Ciriaco P, Carretta A, Calori G, et al. Lung resection for cancer in patients with coronary arterial disease: Analysis of short-term results. Eur J Cardiothorac Surg, 2002, 22(1): 35-40.
17.
18. Dardzińska JA, Małgorzewicz S, Szupryczyńska N, et al. Adherence to the 2021 dietary guidelines of the European Society of Cardiology on cardiovascular disease prevention in residents of the Pomeranian Voivodeship with increased cardiovascular risk. Pol Arch Intern Med, 2023, 133(6): 16418.
19. Sun M, Yang Q, Li M, et al. Association between the severity of coronary artery disease and lung cancer: A pilot cross-sectional study. Arq Bras Cardiol, 2022, 118(2): 478-485.
20. 郭凡. 非小细胞肺癌合并冠心病行同期手术治疗的研究. 天津医科大学, 2020.Guo F. Combined surgery in patients with nonsmall cell lung cancer accompanied bycoronary artery disease. Tianjin Medical University, 2020.
21.
22. Tourmousoglou CE, Apostolakis E, Dougenis D. Simultaneous occurrence of coronary artery disease and lung cancer: What is the best surgical treatment strategy? Interact Cardiovasc Thorac Surg, 2014, 19(4): 673-681.
23.
24.
25.
26.
27.
28.
29. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage ⅢB/Ⅳ non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase Ⅱ study. J Clin Oncol, 2012, 30(17): 2046-2054.
30. Meng Y, Li L, Wang H, et al. Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: A case report. Ann Transl Med, 2022, 10(8): 496.
31. Hu X, Shui Y, Hirano H, et al. PD-L1 antibody enhanced β-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model. Cancer Immunol Immunother, 2023, 72(3): 719-731.
32. Alduais Y, Zhang H, Fan F, et al. Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. Medicine (Baltimore), 2023, 102(8): e32899.
33. Ganti AKP, Loo BW, Bassetti M, et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2021, 19(12): 1441-1464.
34. Markovic M, Mitrovic S, Dagovic A, et al. Does the expression of vascular endothelial growth factor (VEGF) and Bcl-2 have a prognostic significance in advanced non-small cell lung cancer? Healthcare (Basel), 2023, 11(3): 292.

Previous Article
Research progress of effect of non-therapeutic thymectomy and thymectomy on overall health
Next Article
Advances in acute Stanford type A aortic dissection with organ malperfusion

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Risk factors for lung cancer with coronary artery diseases and the advances of treatment

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content